Researchers to re-examine compounds shelved by industry.
Progeria is a rare, lethal disease that ages children so rapidly that they seem to be 80 years old when they are just 10. So patients and families celebrated the news last week of the first therapeutic success against the disease — as did advocates of the notion that abandoned drugs can rise again. A clinical trial has shown improved symptoms in children with the disease who used lonafarnib (L. B. Gordon Proc. Natl Acad. Sci. USA http://doi.org/jfz; 2012), a drug developed by Merck in the 1990s that failed against its original target, head and neck cancer. (...) - by Meredith Wadman, Nature News, 3 October, 2012